InvestorsHub Logo
Post# of 1028
Next 10
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

Re: None

Wednesday, 09/13/2017 12:22:36 PM

Wednesday, September 13, 2017 12:22:36 PM

Post# of 1028
Next 12 months

Patient data, start of Phase 2 (DUR-928), initial Phase 2 data

Complete Phase 3 (POSIMIR®), top-line data, NDA resubmission

REMOXY®ER data generated by Pain Therapeutics to support resubmission in Q1 2018




Next 24 months

Phase 2 data in one or more indications (DUR-928)

POSIMIR®approval and launch by Sandoz

Potential REMOXY®ER approval

At least 1 new collaboration
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRRX News